Chemed Q3: rev $606M (+7.4%), adj EPS $5.64; FY2024 adj EPS guidance cut to $23.00-$23.15 on Roto-Rooter weakness

CHEMED CORP

2024-Q3 EPS reported $13.88 revenue$1,791,294,000

GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).
VITAS net patient revenue $391.4M (+17.3%), ADC 21,785 (+15.5%), adjusted EBITDA $73.1M (+33.1%).
Roto-Rooter revenue $214.8M (-6.9%), adjusted EBITDA $56.4M (-15.8%), margin 26.3% (-275 bps).
FY2024 adjusted EPS guidance revised to $23.00-$23.15 (targeting 13.3%-14.0% growth over 2023) due to softer Roto-Rooter results.
Repurchased 100,000 shares for $57.8M at $578.21/share; cash $238.5M, no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.